MeSH term
Frequency | Condition_Probility | Female | 27 | 0.0 |
Humans | 95 | 0.0 |
Pregnancy | 3 | 0.0 |
Base Sequence | 8 | 0.0 |
Molecular Sequence Data | 9 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 3 | 1.0 |
Organ Specificity | 2 | 0.0 |
Substrate Specificity | 7 | 0.0 |
ATP-Binding Cassette Transporters/*genetics | 8 | 3.0 |
DNA Primers/chemistry | 3 | 0.0 |
Exons | 2 | 0.0 |
Introns | 2 | 0.0 |
Multigene Family | 2 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Polymorphism, Single Nucleotide/*genetics | 2 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Adolescent | 7 | 0.0 |
Adult | 10 | 0.0 |
Case-Control Studies | 2 | 0.0 |
Child | 5 | 0.0 |
Child, Preschool | 4 | 0.0 |
Disease-Free Survival | 3 | 0.0 |
Gene Expression | 3 | 0.0 |
Infant | 4 | 0.0 |
Male | 20 | 0.0 |
Recurrence | 2 | 0.0 |
ATP-Binding Cassette Transporters/*biosynthesis/genetics | 2 | 11.0 |
Cells, Cultured | 9 | 0.0 |
*Neoplasm Proteins | 18 | 2.0 |
*Nerve Tissue Proteins | 2 | 0.0 |
Phenotype | 7 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 62 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 26 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Animals | 31 | 0.0 |
Biological Transport, Active | 2 | 1.0 |
Drug Resistance, Multiple/genetics/*physiology | 2 | 66.0 |
Mice | 16 | 0.0 |
Antineoplastic Agents/pharmacology | 6 | 1.0 |
Cell Line, Tumor | 12 | 0.0 |
Cell Survival | 2 | 0.0 |
Drug Resistance, Neoplasm | 14 | 2.0 |
Flow Cytometry | 10 | 0.0 |
Fluorescent Dyes/pharmacokinetics | 2 | 22.0 |
Middle Aged | 9 | 0.0 |
Mitoxantrone/pharmacology | 7 | 38.0 |
Antineoplastic Agents/*pharmacology | 4 | 0.0 |
Cell Line | 8 | 0.0 |
Drug Resistance, Multiple/*genetics | 3 | 4.0 |
*Mutation | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 5 | 0.0 |
Aged | 8 | 0.0 |
ATP-Binding Cassette Transporters/genetics/*metabolism | 9 | 15.0 |
Benzimidazoles/*metabolism | 2 | 50.0 |
Biological Transport/drug effects | 6 | 2.0 |
Blotting, Western | 7 | 0.0 |
Cell Line/drug effects/metabolism | 2 | 13.0 |
Comparative Study | 10 | 0.0 |
Drug Resistance, Multiple | 12 | 7.0 |
*Drug Resistance, Neoplasm | 8 | 4.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Hematopoiesis/genetics | 2 | 5.0 |
Hematopoietic Stem Cells/*metabolism | 4 | 3.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Neoplasm Proteins/genetics/*metabolism | 4 | 2.0 |
Reverse Transcriptase Polymerase Chain Reaction | 16 | 0.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
ATP-Binding Cassette Transporters/*metabolism | 6 | 7.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Neoplasm Proteins/metabolism | 5 | 1.0 |
P-Glycoprotein/genetics | 3 | 9.0 |
Camptothecin/*analogs & derivatives/*pharmacokinetics/pharmacology | 2 | 100.0 |
Gene Frequency | 3 | 0.0 |
Neoplasm Proteins/*genetics | 4 | 0.0 |
Drug Resistance, Neoplasm/*physiology | 2 | 6.0 |
Glucuronides/metabolism | 2 | 4.0 |
Kinetics | 4 | 0.0 |
Tumor Cells, Cultured | 16 | 0.0 |
Breast Neoplasms/*genetics | 2 | 0.0 |
Drug Resistance, Multiple/genetics | 2 | 4.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 11 | 0.0 |
Topotecan/pharmacology | 3 | 21.0 |
Transfection | 9 | 0.0 |
*Drug Resistance, Multiple | 6 | 5.0 |
Forecasting | 3 | 0.0 |
Biological Transport | 14 | 1.0 |
Cell Survival/drug effects | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
RNA, Neoplasm/genetics/metabolism | 2 | 1.0 |
Time Factors | 3 | 0.0 |
ATP-Binding Cassette Transporters/genetics/*physiology | 3 | 13.0 |
Adenosinetriphosphatase/metabolism | 3 | 2.0 |
Cell Membrane/enzymology | 3 | 1.0 |
Cloning, Molecular | 3 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Spodoptera | 3 | 1.0 |
ATP-Binding Cassette Transporters/*genetics/*metabolism | 3 | 21.0 |
Drug Interactions | 3 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Amino Acid Sequence | 6 | 0.0 |
Gene Expression Profiling | 3 | 0.0 |
Blotting, Northern | 3 | 0.0 |
Cell Division/drug effects | 4 | 0.0 |
Flavonoids/*pharmacology | 4 | 5.0 |
Indoles/pharmacology | 2 | 0.0 |
Tumor Cells, Cultured/drug effects/*metabolism/pathology | 2 | 66.0 |
ATP-Binding Cassette Transporters/*antagonists & inhibitors/metabolism | 2 | 66.0 |
Neoplasm Proteins/*antagonists & inhibitors/metabolism | 2 | 22.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Mitoxantrone/metabolism | 3 | 100.0 |
RNA, Messenger/metabolism | 6 | 0.0 |
Rats | 2 | 0.0 |
Adenosine Triphosphate/metabolism | 4 | 0.0 |
Drug Resistance | 2 | 0.0 |
DNA-Binding Proteins/genetics | 2 | 0.0 |
Immunohistochemistry | 6 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Multidrug Resistance-Associated Proteins/genetics | 2 | 33.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Antimetabolites, Antineoplastic/*pharmacology | 2 | 2.0 |
Fluorouracil/*pharmacology | 2 | 5.0 |
*Gene Expression Profiling | 2 | 0.0 |
*Models, Theoretical | 2 | 3.0 |
Predictive Value of Tests | 2 | 0.0 |
Regression Analysis | 2 | 0.0 |
Stomach Neoplasms/*drug therapy/*genetics | 2 | 100.0 |
Adipose Tissue/blood supply/*cytology | 2 | 100.0 |
Antigens, CD31/analysis | 2 | 2.0 |
Antigens, CD34/analysis | 3 | 0.0 |
Biological Markers/analysis | 3 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Cell Proliferation | 2 | 1.0 |
Endothelium, Vascular/*cytology | 2 | 1.0 |
Hindlimb/blood supply | 2 | 8.0 |
Ischemia/*therapy | 2 | 10.0 |
Mice, Nude | 2 | 0.0 |
Regional Blood Flow | 2 | 1.0 |
Stem Cells/classification/*cytology/metabolism | 2 | 100.0 |
Stromal Cells/metabolism | 3 | 3.0 |
Breast Neoplasms/metabolism | 2 | 1.0 |
Point Mutation | 3 | 0.0 |
Acute Disease | 4 | 0.0 |
Mutation | 3 | 0.0 |
Transduction, Genetic | 3 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
ATP-Binding Cassette Transporters/genetics/metabolism/*physiology | 2 | 25.0 |
Gene Therapy | 3 | 0.0 |
Models, Biological | 4 | 0.0 |
Neoplasm Proteins/genetics/metabolism/*physiology | 2 | 18.0 |
Polymorphism, Genetic | 3 | 0.0 |
Protein Structure, Tertiary | 2 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Drug Resistance, Multiple/*physiology | 2 | 8.0 |
HL-60 Cells | 3 | 0.0 |
Infant, Newborn | 2 | 0.0 |
Blood Loss, Surgical/statistics & numerical data | 2 | 8.0 |
Blood Transfusion/utilization | 2 | 8.0 |
Cost-Benefit Analysis | 2 | 1.0 |
English Abstract | 3 | 0.0 |
Hospital Costs/statistics & numerical data | 2 | 8.0 |
Length of Stay/statistics & numerical data | 2 | 5.0 |
Osteoarthritis, Knee/epidemiology/*surgery | 2 | 8.0 |
*Outcome Assessment (Health Care) | 2 | 4.0 |
Perioperative Care | 2 | 8.0 |
Postoperative Complications/epidemiology | 2 | 4.0 |
Turkey/epidemiology | 2 | 2.0 |
Benzimidazoles/pharmacology | 3 | 7.0 |
Dyes/pharmacology | 2 | 2.0 |
Fluorescent Dyes/pharmacology | 2 | 10.0 |
Protein Binding | 5 | 0.0 |
Chemokines, CC/metabolism | 2 | 4.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
P-Glycoprotein/metabolism | 6 | 9.0 |
Reproducibility of Results | 2 | 0.0 |
Drug Resistance, Neoplasm/genetics | 2 | 2.0 |
NIH 3T3 Cells | 2 | 0.0 |
Promoter Regions (Genetics) | 2 | 0.0 |
Dimerization | 2 | 0.0 |
*Drug Resistance, Neoplasm/genetics | 2 | 22.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Quinolines/pharmacology | 3 | 13.0 |
Antineoplastic Agents/chemistry/*pharmacology | 2 | 8.0 |
Neoplasms/drug therapy/metabolism | 2 | 11.0 |
RNA, Neoplasm/genetics | 2 | 0.0 |
*Drug Resistance | 2 | 4.0 |
ATP-Binding Cassette Transporters/metabolism | 2 | 4.0 |
Multidrug Resistance-Associated Proteins/metabolism | 2 | 20.0 |
Propionates/pharmacology | 2 | 25.0 |
Neoplasm Proteins/genetics | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Adenosine Triphosphate/*metabolism | 2 | 2.0 |
Molecular Structure | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Gene Expression Regulation, Leukemic | 2 | 2.0 |
